GMXIII: Developing a Clinical Genomic Informatics Research Agenda

Survey Results

Marc S. Williams, MD

On behalf of: Pamela Williams, Tejinder Rakhra-Burris, Ken Wiley

Objectives


- Present and discuss survey results
- Compare results of current desiderata questions to GMVII responses
- Identify themes from written comments
- Set the stage for rest of the meeting

Statistics

- 33 respondents (83 invited to participate)
- Response rate 39.8%
- 100% completed the survey
- Extensive written comments

Results

Questions regarding genomic-based clinical informatics tools and resources



				\square		\square	
#	Field	Minimum	Maximum	Mean	Std Deviation	Variance	Count
1	#1: The business model for developing and implementing genomic based clinical informatics tools and resources encourages open source development	1.00	5.00	3.24	1.13	1.29	29
2	#2: Methods for evaluating the clinical utility of a genomic based clinical informatics tools and resources are clearly defined for the research community to use in their research and development plans.	1.00	5.00	3.55	0.97	0.94	29
3	#3: Advancements in storing genomic and genomic based information are adequate to meet the clinical genomic community needs.	1.00	5.00	3.48	0.97	0.94	29
4	#4: Methods related to ontology management and knowledge representation for genomic based clinical interpretation are adequately addressed by the research community.	2.00	5.00	3.62	0 84	0.70	26
5	#5: Methods for integrating analytical interpretations derived by computational models of genomic data into clinical settings are well established.	3.00	5.00	4.11	0.63	0.40	27
6	#6: The genomic medicine community will benefit from having a revised technical desiderata.	1.00	4.00	2.04	<mark>0.18</mark>	0.61	28
7	#7: Efforts to modify clinical workflows to reduce instances of alert fatigue are actively being developed by the genomic medicine community.	2.00	5.00	3.61	0.98	0.95	28
8	#8: Does the Centers for Medicare & amp; Medicaid Services Promoting Interoperability Programs support the integration of genomic and genomic related information into the Electronic Health Record.	2.00	5.00	3.41	0.83	0.70	22


Research Priority?

#	Question	Strongly Agree		Agree		Neither Agree / Disagree		Disagree		Strongly Disagree		Total
5	#5: Methods for integrating analytical interpretations derived by computational models of genomic data into clinical settings are well established.	0.00%	0	0.00%	0	14.81%	4	59.26%	16	25.93%	7	27

Comparison to GM VII (October 2014)

- GMVII focus was on Genomic Clinical Decision Support
- Methodology different
 - \odot Queried on two different scales
 - Importance of a given element
 - Gap between current state and ideal future state
 - \odot Also asked to prioritize elements
- For GMXIII asked to agree or disagree with desiderata, which is mostly similar to importance of a given element

Mean Element Importance-GMVII



- 1. Separation of mol observation from clin interp
- 2. Lossless compression
- 3. Linkage observations to lab methods
- 4. Actionable subsets
- 5. Human /Machine readable
- 6. Changes in understanding
- 7. Discovery science and patient care
- 8. CDS over multiple genes
- 9. CDS Knowledge separate
- 10. EHR generalizability
- 11. Support Gene variants
- 12. Standards: CDS and genomics
- 13. Deploy shared CDS KB
- 14. Access and transmit minimum info for CDS

Comparison of priorities

Ranked high both meetings

#8 CDS knowledge must have the potential to incorporate multiple genes and clinical information

#10 CDS knowledge must have the capacity to support multiple EHR platforms with various data representations with minimal modification

Desiderata ranked high to low GMVII GMXIII 8 8 High) 3 7 5 1 12 13 those data (Low to High) 10 10 2 4 3 11 12 7 (High to Low) 11 4 5 6 9 1 2 13 9 6 Low) 14 14

Changed between meetings (GMVII to GMXIII

#12 Leverage current and developing CDS and genomics standards (Low to High)


#3 Maintain linkage of molecular observations to the laboratory methods used to generate them (Low to

- #1 Maintain separation of primary molecular
- observations from the clinical interpretations of
- #13 Support a CDS knowledge base deployed at and developed by multiple independent organizations
 - #5 Simultaneously support human-viewable formats and machine-readable formats in order to facilitate
 - implementation of decision support rules (High to

Special Relevance #7 Support both individual clinical care and discovery science. (High to Low) Ranked #2 GMVII and #8 for GMXIII (Session 5)

Fig. 3: Virtuous cycles in human genomics research and clinical care.

From: Strategic vision for improving human health at The Forefront of Genomics



Additional themes from free text

- Importance of assessing stakeholder preference and workflow
- Sustainability of resources
- Lack of methods for evaluation of innovation and implementation
- Impact of the consent and regulatory framework

Implications for the research agenda

- Research in genomics and informatics is a "target-rich" environment
- Several priorities are persistent over the last 5 years
- Research should include attention to:
 - \odot Stakeholder engagement and workflow evaluation
 - \odot Development and use of rigorous evaluation methods
 - \odot Consideration of policy and regulatory environment
 - Sustainability

The Meeting

- Survey results including comments included in the meeting materials • Contact Ken or me if you have comments on our interpretation of the results
- Each speaker has received narrative comments from the survey relevant to their topic and has been asked to use those to inform their content
- Keep the overarching implications in mind during discussion

Clarifying Questions